Does Celldex Therapeutics, Inc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Celldex Therapeutics, Inc. (CLDX) 48.4 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 95, returns on capital 0, balance-sheet safety 55, capital discipline 44.

How has CLDX's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 48.4 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

Celldex Therapeutics, Inc.

CLDX · Healthcare · $2.4B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power95

Median gross margin 95.7% over 10y, very stable.

Returns on capital0

Median ROIC -38.3%, above the 9% hurdle in 0% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline44

Owner earnings trend unclear, share count n/a.

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $35.35
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

18 years of fundamentals

The business, in plain English

Celldex Therapeutics, Inc. booked $1.5M of revenue in FY2025 in the Healthcare sector and kept 87.1% of it as gross profit — a high-margin business by that measure. After every other cost, −16748.0% of each revenue dollar reached the bottom line.

Across the filed record, revenue shrank from $15.2M (FY2009) to $1.5M (FY2025) — about −13.3% a year compounded over 16 years.

It earned −45.6% on invested capital in FY2025, with a median of −46.9% across 17 filed years. The Returns on Capital filter above scores it 0/100.

CLDX's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.

The share count rose 107.6% between FY2010 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 44/100.

Put together: Pricing Power is the strongest of the four filters (95/100) and Returns on Capital the weakest (0/100), which is how CLDX lands at 48/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$1.5M FY2025

Gross marginRevenue kept after cost of goods87.1% FY2025

Return on invested capitalOperating profit on the capital employed−45.6% FY2025

Owner earningsCash an owner could take out−$258.1M FY2025

Gaps in a line mean that item isn’t in CLDX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale48.4 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — CLDX has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#129 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#127MYO MYOMO, INC.48.9 out of 100, Shallow moatShallow moat
#128VIR Vir Biotechnology, Inc.48.6 out of 100, Shallow moatShallow moat
#130NEPH NEPHROS, INC.48.0 out of 100, Shallow moatShallow moat
#131PAHC Phibro Animal Health Corporation47.9 out of 100, Shallow moatShallow moat

Compare CLDX with its nearest peers →All Healthcare companies on the Index →

Common questions about CLDX

Does Celldex Therapeutics, Inc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Celldex Therapeutics, Inc. (CLDX) 48.4 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 95, returns on capital 0, balance-sheet safety 55, capital discipline 44.
How has CLDX's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 48.4 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows CLDX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/CLDX"
  width="340" height="150" style="border:0"
  title="CLDX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell CLDX. See the disclaimer.